Results from three independent discovery campaigns show Optimers with up to 142x higher affinity for more sensitive assays. The three main reasons people explore Optimer development are: There is no…
Cell screens can be included in the aptamer discovery process, providing built-in validation for your binder. In most affinity ligand discovery processes, whether for…
Using multiple discovery methods in aptamer development provides better binders. Learn why multiple discovery methods are important, which is right for you and how they can be combined for…
Uncover disease-defining biomarkers by starting with cellular phenotypes, not predetermined targets. Why do we need new biomarkers? Traditional biomarker discovery relies on testing predetermined targets…
Optimer-Fc integrates the benefits of Optimer binders with the Fc portion of an antibody to enhance the target range and selectivity of immunohistochemistry (IHC) reagent to advance analysis of…
Optimer® are novel reagents for use in IHC applications to localise new biomarkers and improve accuracy for current biomarkers, in both FFPE and frozen tissues. Download this application note to…
When selecting the right IHC reagent make sure you consider these three factors and find out how IHC aptamers can help ensure success from the start. Immunohistochemistry, IHC for short,…
Affinity binders are the workhorses of assays and methods across the life sciences. From biologics to bioprocessing ligands and research reagents, the requirements for affinity binders vary according to…
Your research is unique. We tailor your Optimer discovery strategy to match, delivering the highest chance of success and the best Optimer performance. Download this booklet to learn how: …
Not all protein-binding aptamers are developed equally. And they shouldn’t be. When developing aptamers to protein targets the ‘how’ is just as important as the ‘what’. The ‘what’ is what…
